Vanda Pharmaceuticals Inc VNDA

NAS: VNDA | ISIN: US9216591084   30/04/2025
4,510 USD (+1,81%)
(+1,81%)   30/04/2025

23 april 2025 · FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA · Persbericht

7 april 2025 · Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting · Persbericht

31 maart 2025 · Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia · Persbericht

11 september 2024 · Vanda Pharmaceuticals Announces Participation in the 2024 Cantor Global Healthcare Conference · Persbericht

4 september 2024 · Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference · Persbericht

29 augustus 2024 · Vanda Pharmaceuticals Announces Participation in the Wells Fargo 2024 Healthcare Conference · Persbericht

31 juli 2024 · Vanda Pharmaceuticals Reports Second Quarter 2024 Financial Results · Persbericht

26 juli 2024 · Vanda Pharmaceuticals to Announce Second Quarter 2024 Financial Results on July 31, 2024 · Persbericht

1 juli 2024 · Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and Apotex · Persbericht

20 juni 2024 · Vanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover Proposals Are Not in the Best Interests of the Company and its Shareholders · Persbericht

13 juni 2024 · Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak · Persbericht

6 juni 2024 · Vanda Pharmaceuticals Confirms Receipt of Unsolicited, Non-Binding Indication of Interest from Cycle Group Holdings Ltd. · Persbericht

30 mei 2024 · Vanda Pharmaceuticals Announces Participation in the Jefferies 2024 Global Healthcare Conference · Persbericht

30 mei 2024 · Vanda Pharmaceuticals Announces Completion of Transfer of FDA Marketing Authorization for PONVORY® · Persbericht

29 mei 2024 · Vanda Pharmaceuticals Announces Presentations at SLEEP 2024 · Persbericht

24 mei 2024 · Vanda Pharmaceuticals Board of Directors Determines that Revised Unsolicited Takeover Proposal is Not in the Best Interests of the Company and its Shareholders · Persbericht

15 mei 2024 · Vanda Pharmaceuticals Reports Positive Results from a Second Phase III Study of Tradipitant in Motion Sickness · Persbericht

8 mei 2024 · Vanda Pharmaceuticals Reports First Quarter 2024 Financial Results · Persbericht

7 mei 2024 · Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak · Persbericht

30 april 2024 · Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024 · Persbericht

Mijn selecties